These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3180823)

  • 1. Deferoxamine for the diagnosis and treatment of aluminum-associated osteodystrophy.
    Charhon S; el Yafi S; Gaillard M; Beruard M; Janin G; Accominotti M; Traeger J; Meunier PJ
    Contrib Nephrol; 1988; 64():160-9. PubMed ID: 3180823
    [No Abstract]   [Full Text] [Related]  

  • 2. The interaction of parathyroid hormone and aluminum in renal osteodystrophy.
    Slatopolsky E
    Kidney Int; 1987 Mar; 31(3):842-54. PubMed ID: 3573543
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy.
    Milliner DS; Nebeker HG; Ott SM; Andress DL; Sherrard DJ; Alfrey AC; Slatopolsky EA; Coburn JW
    Ann Intern Med; 1984 Dec; 101(6):775-9. PubMed ID: 6208838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
    Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dialysis osteomalacia and aluminum toxicity: a form of renal osteodystrophy.
    Felsenfeld AJ
    ANNA J; 1985 Jun; 12(3):189-91. PubMed ID: 3848318
    [No Abstract]   [Full Text] [Related]  

  • 6. Aluminum and renal osteodystrophy.
    Nebeker HG; Coburn JW
    Annu Rev Med; 1986; 37():79-95. PubMed ID: 3085581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of aluminum in uremic osteodystrophy.
    Luciani L; Rovelli E; Colleoni N; Mocetti P; Ballanti P; Bonucci E; D'Amico G
    Contrib Nephrol; 1990; 77():168-76. PubMed ID: 2188785
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prevention and treatment of renal osteodystrophy: present and future].
    Fernández E; Craver L
    Nefrologia; 2006; 26 Suppl 3():19-27. PubMed ID: 17469423
    [No Abstract]   [Full Text] [Related]  

  • 9. [Aluminum associated bone disease in patients undergoing long-term hemodialysis].
    Hino M; Yamamoto I; Shigeno C; Aoki J; Torizuka K; Iwamoto N; Yamazaki S; Fukuda T; Kondo M; Yamamoto N
    Nihon Naibunpi Gakkai Zasshi; 1986 Jun; 62(6):724-36. PubMed ID: 3758431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aluminium-related osteodystrophy and desferrioxamine treatment: role of phosphorus.
    Jorgetti V; Soeiro NM; Mendes V; Pereira RC; Crivellari ME; Coutris G; Borelli A; Leite MO; Nussenzweig I; Marcondes M
    Nephrol Dial Transplant; 1994; 9(6):668-74. PubMed ID: 7970094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal glomerular osteodystrophy.
    Genuth SM
    Postgrad Med; 1972 Sep; 52(3):211-7. PubMed ID: 4560232
    [No Abstract]   [Full Text] [Related]  

  • 12. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of renal osteodystrophy in hemodialysis patients.
    DeVita MV; Rasenas LL; Bansal M; Gleim GW; Zabetakis PM; Gardenswartz MH; Michelis MF
    Medicine (Baltimore); 1992 Sep; 71(5):284-90. PubMed ID: 1522804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of aluminum in renal osteodystrophy.
    Sherrard DJ
    Mayo Clin Proc; 1993 May; 68(5):510-1. PubMed ID: 7683073
    [No Abstract]   [Full Text] [Related]  

  • 15. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.
    Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
    Lechleitner P; Gmeiner R; Beck G; König P
    Wien Med Wochenschr; 1987 Aug; 137(14-15):355-60. PubMed ID: 3673100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for renal osteodystrophy: a multivariant analysis.
    Pei Y; Hercz G; Greenwood C; Segre G; Manuel A; Saiphoo C; Fenton S; Sherrard D
    J Bone Miner Res; 1995 Jan; 10(1):149-56. PubMed ID: 7747622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aluminum load and histological bone disease in hemofiltration and hemodialysis.
    Fournier A; Moriniere P; Fohrer P; Leflon P; de Fremont JF; Marié A; Westeel PF; Renaud H; Tahiri Y; Idrissi A
    Kidney Int Suppl; 1988 Mar; 24():S168-70. PubMed ID: 3163040
    [No Abstract]   [Full Text] [Related]  

  • 19. Renal osteodystrophy.
    Coburn JW; Henry DA
    Adv Intern Med; 1984; 30():387-424. PubMed ID: 6397042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of aluminum-associated bone disease in long-term hemodialysis patients.
    Iwamoto N; Ono T; Yamazaki S; Fukuda T; Kondo M; Yamamoto N; Hiratake Y; Masugi Y; Kubo Y; Hino M
    Nephron; 1986; 42(3):204-9. PubMed ID: 3945360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.